Navigation Links
Unigene's Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
Date:11/30/2011

rally-restricted kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain.  In a previous randomized, placebo-controlled Phase II study, CR845 demonstrated evidence of analgesic efficacy when administered as a single intravenous dose to women following laparoscopic hysterectomy.  In addition to decreases in reported pain levels, patients receiving CR845 required substantially lower amounts of post-operative opioids (narcotics) and showed a significant reduction in the incidence of post-operative nausea and vomiting. A multicenter double-blind, randomized, placebo-controlled 200-patient Phase II trial is ongoing to evaluate the efficacy and safety of intravenous CR845 when administered both pre- and post-operatively in women undergoing laparoscopic hysterectomy. Analysis of this trial is expected in 1Q'12.  To date, more than 150 human subjects have been exposed to CR845 with no cases of the dysphoria or hallucinations that have been reported with centrally-acting kappa opioids.  For more information visit: www.caratherapeutics.com.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expert
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
5. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. Nventa Develops Proprietary Vaccine Adjuvant
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
11. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)... 25, 2014  Medtronic,s roughly $43 billion ... widely discussed in the media for its US ... stronger leading player in one of the fastest ... healthcare market research firm said  the two companies ... diverse set of solutions spanning inpatient to home ...
(Date:11/26/2014)... Nov. 25, 2014  Breckenridge Pharmaceutical, Inc. announced ... ANDA agreement with Pii (Pharmaceutics International, Inc.) ( ... Breckenridge and Pii expect to develop and commercialize ... agreement, Pii will develop, manufacture and supply the ... products under its own label.  The drugs, comprised ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... CHICAGO, Sept. 10 Celsis In Vitro, Inc. (Celsis ... for the Northern District of Illinois in Chicago has ... and Life Technologies (the Defendants) due to their infringement ... Technologies of Carlsbad, California (Nasdaq: LIFE ) ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), ... pharmaceutical, biotechnology, and medical device industries, today announced that ... President and Chief Executive Officer and a director of ... search for a successor.  Dr. McKelvey will continue in ...
Cached Medicine Technology:Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 2Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 3ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 2ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 3
(Date:11/27/2014)... 2014 RBSEO Services, a well-established ... optimization service just at $99. RBSEO Services knows ... afford costly search engine optimization service. So, the ... affordablity and requirements into consideration. , The ... has not compromised with the service quality. The ...
(Date:11/27/2014)... CA, (PRWEB) November 26, 2014 ... browser-based presentation platform, focused on increasing audience engagement ... Britannic Technologies. Lintelus’ software platform includes a multitude ... and presenter in a collaborative, interactive multi-screen environment. ... and the presentation in real time on their ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Dr. Parsa ... themselves this holiday season! With Parsa Mohebi Hair Restoration’s ... off of their next FUE procedure, making it that ... FUE—which stands for “Follicular Unit Extraction”—is an advanced variety ... traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike FUT, ...
(Date:11/26/2014)... iFitDress.com, a well-known wedding dress manufacturer ... sweet 16 cocktail dresses . Included in the new ... Furthermore, all of these charming outfits are offered at ... company has promised that all of the sweet 16 ... is worth mentioning that all of them are set ...
(Date:11/26/2014)... By Alex Kramer ... -- People with rheumatoid arthritis may be more likely to ... to new research. The study found that those who ... remission. Being underweight also lowered the odds of remission. ... overweight population," said Dr. Susan Goodman, the study,s lead author ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:iFitDress.com: Trendy Sweet 16 Cocktail Dresses Unveiled 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... ... Association (AWWA) is urging students and job seekers to explore the water sector to discover ... rewarding. , ... May 4, 2010 -- As Drinking Water Week continues, the American Water Works Association ...
... VANCOUVER, BRITISH COLUMBIA Adolescents who don,t get enough ... play video games or text their friends. They also ... May 4 at the Pediatric Academic Societies (PAS) annual ... have shown a relationship between sleep and weight issues, ...
... ... use competitive intelligence data to develop actionable marketing strategies with the help of Evolve Creative ... ... marketing and design firm, now offers businesses in Hamilton a competitive intelligence analysis ...
... The Carrousel Yacht ... Florida. Renowned for its award-winning gourmet cuisine, the Carrousel Yacht is a boutique operation providing ... by Great Bay Yacht Charters and has been in the hospitality industry and yacht charter ... ...
... enzyme deficiency disorder, is one of many conditions with few ... today in Blood , the journal of the American ... II clinical trial of eliglustat tartrate, an oral therapy in ... genetic disorder affecting an estimated 1 in 50,000 to 1 ...
... a specific type of dopamine receptor gene respond ... without the genotype, according to new research from ... come from the first-ever placebo-controlled pharmacogenetic drug trial ... to evaluate variants of the DRD4 dopamine receptor ...
Cached Medicine News:Health News:During Drinking Water Week 2010, Water Sector Urges Students, Job Seekers to Work for Water 2Health News:Less sleep may add up to more pounds in adolescents 2Health News:Evolve Creative Media Offers Competitive Market Analysis to Assist Small Businesses in Hamilton 2Health News:Carrousel Yacht: Miami Private Yacht Charters With Style, Taste and Value 2Health News:Carrousel Yacht: Miami Private Yacht Charters With Style, Taste and Value 3Health News:Phase II study of an oral therapy for Gaucher disease yields positive results 2Health News:Research helps end guesswork in prescribing ADHD drug 2
... series SV stereomicroscopes are ... type. Thanks to their ... optimally adapt to the ... is an advantage which ...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... Fluor 20x Water Dipping Objective is ... research where the objective is actually ... or brain slice. The objective provides ... with a numberical aperature of 0.50, ...
Medicine Products: